Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
2(15%)
Results Posted
120%(6 trials)
Terminated
3(23%)

Phase Distribution

Ph not_applicable
1
8%
Ph early_phase_1
1
8%
Ph phase_3
5
38%
Ph phase_4
2
15%
Ph phase_2
3
23%

Phase Distribution

1

Early Stage

3

Mid Stage

7

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
5(41.7%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(5)
Terminated(4)
Other(1)

Detailed Status

Completed5
Terminated3
Recruiting1
unknown1
Withdrawn1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
62.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (8.3%)
Phase 23 (25.0%)
Phase 35 (41.7%)
Phase 42 (16.7%)
N/A1 (8.3%)

Trials by Status

completed538%
terminated323%
recruiting18%
unknown18%
withdrawn18%
enrolling_by_invitation18%
active_not_recruiting18%

Recent Activity

Clinical Trials (13)

Showing 13 of 13 trials
NCT05492578Phase 2

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

Enrolling By Invitation
NCT07498374Not Applicable

Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial

Recruiting
NCT05345171Phase 3

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

Active Not Recruiting
NCT04660539Phase 3

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Completed
NCT05750797

The Nationwide Real-world Status of Oral Corticosteroid Use in Patients With Asthma

Unknown
NCT01380028Phase 3

Interest of Oral Corticosteroids in the Treatment of Chronic Subdural Hematomas

Terminated
NCT03457025Early Phase 1

Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome

Withdrawn
NCT01536535Phase 4

Predicting Response to Standardized Pediatric Colitis Therapy

Completed
NCT02537691Phase 4

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

Completed
NCT02046603Phase 3

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent

Completed
NCT01499355Phase 2

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis

Terminated
NCT01930890Phase 2

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Terminated
NCT00720798Phase 3

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13